FaCT Trial: Improving Genetic Testing for BRCA1/2 Mutations
This study, called the FaCT Trial, is looking at better ways to help family members of people with BRCA1 or BRCA2 mutations get genetic testing. You might be able to join if you are 18 or older, speak English or Spanish, and are a patient at New York Presbyterian/Weill Cornell Medical Center, MD Anderson Cancer Center, Duke University, or Columbia University. The study compares a standard approach (a family letter) with a new approach that includes an educational video, a mailed saliva kit for genetic testing, and telephone counseling. The goal is to see if the new approach helps more first-degree relatives (like parents, siblings, or children) get tested within 6 months. The study is currently recruiting participants.
- Study design
- This is a randomized controlled trial comparing two approaches for genetic testing. It plans to enroll up to 524 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is measured at 6 months after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
FaCT Trial (Facilitated Cascade Testing Trial)
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Melissa K Frey, MD, MS · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Proportion of genetic testing by 6 months among FDRs on each study arm6 months
To compare proportion of completion of genetic testing at 6 months follow-up among first degree family relatives (referred to herein as "FDR": son, daughter, full-brother, full-sister, mother, father) of patients with a confirmed BRCA1/2 mutation (referred to as "proband") randomized to the intervention arm versus the standard of care.